Vanguard Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,107,305
| Closed | -$3.9M | – | 4616 |
|
|
2023
Q1 | $3.9M | Buy |
2,107,305
+474,127
| +29% | +$587K | ﹤0.01% | 3418 |
|
|
2022
Q4 | $1.81M | Buy |
1,633,178
+7,321
| +0.5% | +$10.4K | ﹤0.01% | 3700 |
|
|
2022
Q3 | $3.8M | Buy |
1,625,857
+22,883
| +1% | +$81K | ﹤0.01% | 3465 |
|
|
2022
Q2 | $4.86M | Sell |
1,602,974
-10,531
| -0.7% | -$51.2K | ﹤0.01% | 3392 |
|
|
2022
Q1 | $11M | Buy |
1,613,505
+21,473
| +1% | +$153K | ﹤0.01% | 3102 |
|
|
2021
Q4 | $13.3M | Buy |
1,592,032
+148,603
| +10% | +$1.22M | ﹤0.01% | 3067 |
|
|
2021
Q3 | $10.7M | Buy |
1,443,429
+36,604
| +3% | +$227K | ﹤0.01% | 3201 |
|
|
2021
Q2 | $9.57M | Buy |
1,406,825
+46,060
| +3% | +$383K | ﹤0.01% | 3227 |
|
|
2021
Q1 | $14M | Buy |
1,360,765
+459,705
| +51% | +$5.03M | ﹤0.01% | 2971 |
|
|
2020
Q4 | $6.31M | Sell |
901,060
-1,932
| -0.2% | -$15K | ﹤0.01% | 3246 |
|
|
2020
Q3 | $7.37M | Sell |
902,992
-79,871
| -8% | -$495K | ﹤0.01% | 2954 |
|
|
2020
Q2 | $6.78M | Sell |
982,863
-28,962
| -3% | -$156K | ﹤0.01% | 2946 |
|
|
2020
Q1 | $4.81M | Buy |
1,011,825
+72,287
| +8% | +$416K | ﹤0.01% | 2990 |
|
|
2019
Q4 | $8.2M | Buy |
939,538
+74,850
| +9% | +$405K | ﹤0.01% | 2952 |
|
|
2019
Q3 | $2.88M | Buy |
864,688
+64,538
| +8% | +$258K | ﹤0.01% | 3323 |
|
|
2019
Q2 | $3.96M | Buy |
800,150
+188,540
| +31% | +$1M | ﹤0.01% | 3249 |
|
|
2019
Q1 | $3.79M | Buy |
611,610
+133,739
| +28% | +$646K | ﹤0.01% | 3234 |
|
|
2018
Q4 | $1.61M | Sell |
477,871
-298,145
| -38% | -$1.39M | ﹤0.01% | 3438 |
|
|
2018
Q3 | $5.04M | Buy |
776,016
+41,945
| +6% | +$312K | ﹤0.01% | 3236 |
|
|
2018
Q2 | $5.62M | Buy |
734,071
+128,000
| +21% | +$1.85M | ﹤0.01% | 3173 |
|
|
2018
Q1 | $13.5M | Sell |
606,071
-56,861
| -9% | -$1.26M | ﹤0.01% | 2667 |
|
|
2017
Q4 | $8.45M | Buy |
662,932
+83,772
| +14% | +$1.23M | ﹤0.01% | 2897 |
|
|
2017
Q3 | $9.02M | Buy |
579,160
+324,100
| +127% | +$4.58M | ﹤0.01% | 2858 |
|
|
2017
Q2 | $3.58M | Buy |
255,060
+141,096
| +124% | +$3.02M | ﹤0.01% | 3204 |
|
|
2017
Q1 | $2.51M | Buy |
+113,964
| New | +$2.41M | ﹤0.01% | 3311 |
|
Other funds holding JNCE
Vanguard Group's JNCE Position: Q2 2023 in Review
Vanguard Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 2,107,305 shares — an estimated $3.9M sold.
Vanguard Group first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $14M in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Vanguard Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Vanguard Group sold 2,107,305 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.9M.
- Vanguard Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Vanguard Group's Jounce Therapeutics, Inc. Common Stock position peaked at $14M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.